ARID1A and cancer: Although not considered directly druggable, ARID1A deficiency in cancer has been associated with perturbed regulation of the antioxidant system, namely the balance of intra‐cellular glutathione and reactive oxygen species levels, thus rendering ARID1A‐deficient cancer cells vulnerable to further inhibition of the glutathione metabolic pathway.[102] With small molecule inhibitors (e.g., APR‐246) in clinical trials, further optimization of glutathione‐targeted therapeutic interventions in ARID1A‐deficient cancer settings is warranted.